Kymera Therapeutics (KYMR) Equity Ratio (2019 - 2025)
Kymera Therapeutics (KYMR) has disclosed Equity Ratio for 7 consecutive years, with 0.91 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio rose 6.09% to 0.91 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.91, a 6.09% increase, with the full-year FY2025 number at 0.91, up 6.09% from a year prior.
- Equity Ratio was 0.91 for Q4 2025 at Kymera Therapeutics, up from 0.86 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.91 in Q4 2025 to a low of 0.59 in Q1 2021.
- A 5-year average of 0.78 and a median of 0.78 in 2022 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: soared 30.18% in 2021, then decreased 15.59% in 2023.
- Kymera Therapeutics' Equity Ratio stood at 0.76 in 2021, then increased by 7.13% to 0.81 in 2022, then fell by 15.59% to 0.69 in 2023, then rose by 24.55% to 0.85 in 2024, then grew by 6.09% to 0.91 in 2025.
- Per Business Quant, the three most recent readings for KYMR's Equity Ratio are 0.91 (Q4 2025), 0.86 (Q3 2025), and 0.86 (Q2 2025).